tetano
Editor, Senior Moderator
Int Immunol
. 2022 Jul 2;dxac031.
doi: 10.1093/intimm/dxac031. Online ahead of print.
Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021
Kun Xu[SUP] 1 2 [/SUP], Chunxiang Fan[SUP] 3 [/SUP], Yuxuan Han[SUP] 4 [/SUP], Lianpan Dai[SUP] 2 4 5 [/SUP], George F Gao[SUP] 4 5 [/SUP]
Affiliations
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) pandemic has caused a disaster for public health in the last 2 years, without any sign of an ending. Various vaccines were developed rapidly as soon as the outbreak occurred. Clinical trials demonstrated the reactogenicity, immunogenicity and protection efficacy in humans, and some of the vaccines have been approved for clinical use. However, waves of infections such as the recently circulating Omicron variant still occur. Newly emerging variants, especially the variants of concern, and waning humoral responses pose serious challenges to the control of the COVID-19 pandemic. Previously, we summarized the humoral and cellular immunity, safety profiles and protection efficacy of COVID-19 vaccines with clinical data published by 21 May 2021. In this review, we summarize and update the published clinical data of COVID-19 vaccines and candidates up to December 31, 2021.
Keywords: SARS-CoV-2; antibody; cellular immune response; vaccine effectiveness; vaccine efficacy.
. 2022 Jul 2;dxac031.
doi: 10.1093/intimm/dxac031. Online ahead of print.
Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021
Kun Xu[SUP] 1 2 [/SUP], Chunxiang Fan[SUP] 3 [/SUP], Yuxuan Han[SUP] 4 [/SUP], Lianpan Dai[SUP] 2 4 5 [/SUP], George F Gao[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35778913
- DOI: 10.1093/intimm/dxac031
Abstract
The unprecedented coronavirus disease 2019 (COVID-19) pandemic has caused a disaster for public health in the last 2 years, without any sign of an ending. Various vaccines were developed rapidly as soon as the outbreak occurred. Clinical trials demonstrated the reactogenicity, immunogenicity and protection efficacy in humans, and some of the vaccines have been approved for clinical use. However, waves of infections such as the recently circulating Omicron variant still occur. Newly emerging variants, especially the variants of concern, and waning humoral responses pose serious challenges to the control of the COVID-19 pandemic. Previously, we summarized the humoral and cellular immunity, safety profiles and protection efficacy of COVID-19 vaccines with clinical data published by 21 May 2021. In this review, we summarize and update the published clinical data of COVID-19 vaccines and candidates up to December 31, 2021.
Keywords: SARS-CoV-2; antibody; cellular immune response; vaccine effectiveness; vaccine efficacy.